Antiplatelet and antithrombotic treatment in secondary prevention of cardiovascular events in patients with peripheral artery and polyvascular disease, the ESC 2024 guidelines Review article
Article Sidebar
Published:
Dec 31, 2024
Keywords:
cardiovascular disease, peripheral artery disease, rivaroxaban, acetylsalicylic acid
Main Article Content
Abstract
Patients with lower extremity peripheral artery disease are at increased risk of major adverse cardiovascular events and major adverse limb events. The combination of rivaroxaban 2.5 mg twice daily and acetylsalicylic acid significantly lowered the incidence of major adverse cardiovascular events, major adverse limb events and the related complications, and this combination should be considered as an important therapy for patients with peripheral artery disease.
Article Details
How to Cite
Gierlak, W., & Kuch, M. (2024). Antiplatelet and antithrombotic treatment in secondary prevention of cardiovascular events in patients with peripheral artery and polyvascular disease, the ESC 2024 guidelines. Medycyna Faktow (J EBM), 17(4(65), 464-468. https://doi.org/10.24292/01.MF.0424.05
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Anththrombotic Trialists’ Collaboration; Baigent C, Blackwell L, Collins R, et al.: Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009; 373: 1849-60.
2. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 1996; 348(9038): 1329-39.
3. Bhatt DL, Fox KAA, Hacke W et al.; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006; 354(16): 1706-17.
4. Reaume KT, Regal RE, Dorsch MP. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use. Ann Pharmacother. 2008; 42: 550-7.
5. The Warfarin Antiplatelet Vascular Evaluation Trial Investigators; Anand S, Yusuf S, Xie C et al. Oral Anticoagulant and Antiplatelet Therapy and Peripheral Arterial Disease. N Engl J Med. 2007; 357: 217-27.
6. Eikelboom JW, Connolly SJ, Bosch J et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017; 377: 1319-30.
7. Kaplovitch E, Eikelboom JW, Dyal L et al. Rivaroxaban and aspirin in patients with symptomatic lower extremity peripheral artery disease: a subanalysis of the COMPASS randomized clinical trial. JAMA Cardiol. 2021; 6: 21-9.
8. Bonaca MP, Bauersachs RM, Anand SS et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020; 382: 1994-2004.
9. Eikelboom JW, Bhatt DL, Fox KAA et al. Mortality benefit of rivaroxaban plus aspirin in patients with chronic coronary or peripheral artery disease. J Am Coll Cardiol. 2021; 78: 14-23.
10. Steffel J, Eikelboom JW, Anand SS et al. The COMPASS trial: net clinical benefit of low-dose rivaroxaban plus aspirin as compared with aspirin in patients with chronic vascular disease. Circulation. 2020; 142: 40-8.
11. Eikelboom JW, Bosch J, Connolly SJ et al. Long-term treatment with the combination of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: outcomes during the open label extension of the COMPASS trial. Eur Heart J Cardiovasc Pharmacother. 2022; 8: 786-95.
12. Mazzolai L, Teixido-Tura G, Lanzi S et al. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases. Developed by the task force on the management of peripheral arterial and aortic diseases of the European Society of Cardiology (ESC). Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS), the European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN), and the European Society of Vascular Medicine (ESVM). Eur Heart J. 2024; 45: 3538-700. https://doi.org/10.1093/eurheartj/ehae179.
13. Rostek-Bogacka M, Gierlak W, Kuch M. Doustne leki przeciwzakrzepowe niebędące antagonistami witaminy K (NOAC) w chorobach sercowo-naczyniowych. In: NOAC w praktyce klinicznej – vademecum lekarza pierwszego kontaktu. Kuch M, Pruszczyk P, Hryniewiecki T (eds.). Medical Education, Warszawa 2018.
14. ten Cate H, Guzik T, Eikelboom J et al. Pleiotropic actions of factor Xa inhibition in cardiovascular prevention: mechanistic insights and implications for anti-thrombotic treatment. Cardiovasc Res. 2021; 117: 2030-44.
15. Barylski M. Nowa era trombokardiologii, czyli naczyniowa dawka riwaroksabanu w leczeniu przeciwzakrzepowym chorób miażdżycowych. Dlaczego, kiedy i u kogo? Medycyna Faktów 2024; 17(2): 232-9.
2. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 1996; 348(9038): 1329-39.
3. Bhatt DL, Fox KAA, Hacke W et al.; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006; 354(16): 1706-17.
4. Reaume KT, Regal RE, Dorsch MP. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use. Ann Pharmacother. 2008; 42: 550-7.
5. The Warfarin Antiplatelet Vascular Evaluation Trial Investigators; Anand S, Yusuf S, Xie C et al. Oral Anticoagulant and Antiplatelet Therapy and Peripheral Arterial Disease. N Engl J Med. 2007; 357: 217-27.
6. Eikelboom JW, Connolly SJ, Bosch J et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017; 377: 1319-30.
7. Kaplovitch E, Eikelboom JW, Dyal L et al. Rivaroxaban and aspirin in patients with symptomatic lower extremity peripheral artery disease: a subanalysis of the COMPASS randomized clinical trial. JAMA Cardiol. 2021; 6: 21-9.
8. Bonaca MP, Bauersachs RM, Anand SS et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020; 382: 1994-2004.
9. Eikelboom JW, Bhatt DL, Fox KAA et al. Mortality benefit of rivaroxaban plus aspirin in patients with chronic coronary or peripheral artery disease. J Am Coll Cardiol. 2021; 78: 14-23.
10. Steffel J, Eikelboom JW, Anand SS et al. The COMPASS trial: net clinical benefit of low-dose rivaroxaban plus aspirin as compared with aspirin in patients with chronic vascular disease. Circulation. 2020; 142: 40-8.
11. Eikelboom JW, Bosch J, Connolly SJ et al. Long-term treatment with the combination of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: outcomes during the open label extension of the COMPASS trial. Eur Heart J Cardiovasc Pharmacother. 2022; 8: 786-95.
12. Mazzolai L, Teixido-Tura G, Lanzi S et al. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases. Developed by the task force on the management of peripheral arterial and aortic diseases of the European Society of Cardiology (ESC). Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS), the European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN), and the European Society of Vascular Medicine (ESVM). Eur Heart J. 2024; 45: 3538-700. https://doi.org/10.1093/eurheartj/ehae179.
13. Rostek-Bogacka M, Gierlak W, Kuch M. Doustne leki przeciwzakrzepowe niebędące antagonistami witaminy K (NOAC) w chorobach sercowo-naczyniowych. In: NOAC w praktyce klinicznej – vademecum lekarza pierwszego kontaktu. Kuch M, Pruszczyk P, Hryniewiecki T (eds.). Medical Education, Warszawa 2018.
14. ten Cate H, Guzik T, Eikelboom J et al. Pleiotropic actions of factor Xa inhibition in cardiovascular prevention: mechanistic insights and implications for anti-thrombotic treatment. Cardiovasc Res. 2021; 117: 2030-44.
15. Barylski M. Nowa era trombokardiologii, czyli naczyniowa dawka riwaroksabanu w leczeniu przeciwzakrzepowym chorób miażdżycowych. Dlaczego, kiedy i u kogo? Medycyna Faktów 2024; 17(2): 232-9.